Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor

Antiviral Research

Volumn 29, Issue 2-3, 1996, Pages 269-277

  Turpin, Jim A ^a   Schaeffer, Catherine A ^a   Bu, Ming ^a   Graham, Lisa ^a   Buckheit Jr , Robert W ^b   Clanton, David ^a   Rice, William G ^a  

^a SAIC FREDERICK INC   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

antivirals; human immunodeficiency virus type 1 (HIV 1); lymphocytes; monocytes; saliva; secretory leukocyte protease inhibitor (SLPI)

Indexed keywords

3 NITROSOBENZAMIDE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MONOCYTE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TARGET CELL; VIRUS ADSORPTION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029883543     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00907-8     Document Type: Article

References (19)

1. Archibald, D.W. and Cole, G.A. (1990) In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res. Hum. Retrovir. 6, 1425-1432.
2. Bergey, E.J., Cho, M.-I. Blumberg, B.M., Hammarskjold, M.-L., Rekosh, D., Epstein, L.G. and Levins, M.J. (1994) Interaction of HIV-1 and human salivary mucins. J. Acquir. Immune. Defic. Syndr. 7, 995-1002.
3. Clanton, D.J., Buckheit, R.W., Jr., Terpening, S.J., Kiser, R., Mongelli, N., Borgia, A.L., Schultz, R., Narayanan, V., Bader, J.P. and Rice, W.G. (1995) Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res. 27, 335-354.
4. Cushman, M., Golebiewski, W.M., McMahon, J.B., Buckheit, R.W., Jr., Clanton, D.J., Weislow, O., Haugwitz, R.D., Bader, J.P., Graham, L. and Rice, W.G. (1994) Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus production. J. Med. Chem. 37, 3040-3050.
5. Fox, P.C., Wolff, A., Yeh, C.-K., Atkinson, J.C. and Baum, B.J. (1988) Saliva inhibits HIV-1 infectivity. J. Am. Dent. Assoc. 116, 635-637.
6. Fox, P.C., Wolff, A., Yeh, C.-K., Atkinson, J.C. and Baum, B.J. (1989) Salivary inhibition of HIV-1 infectivity: functional properties and distribution in men, women, and children. J. Am. Dent. Assoc. 118, 709-711.
7. Hattori, T., Koito, A., Takatsuki, K., Kido, H. and Katanuma, N. (1989) Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection. Fed. Eur. Biochem. Soc. Lett. 248, 48-52.
8. Kaplan, G. and Gaudernack, G. (1982) In vitro differentiation of human monocytes. J. Exp. Med. 156, 1101-1114.
9. Kido, H., Fukutomi, A. and Katunuma, N. (1990) A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1. Purification and characterization. J. Biol. Chem. 265, 21979-21985.
10. Kido, H., Fukutomi, A. and Katunuma, N. (1991) Tryptase TL2 in the membrane of human T4+ lymphocytes is a novel binding protein of the V3 domain of HIV-1 envelope glycoprotein gp120. Fed. Eur. Biochem. Soc. Lett. 286, 233-236.
11. McNeely, T.B., Dealy, M., Dripps, D.J., Orenstein, J.M., Eisenberg, S.P. and Wahl, S.M. (1995) Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Invest. 96, 456-464.
12. Rice, W.G. and Bader, J.P. (1995) Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals. In: J.T. August, M.W. Anders, F. Murad and J.T. Coyle (Eds), Advances in Pharmacology, Vol. 33, pp. 389-438. Academic Press, Inc., San Diego, CA.
13. Rice, W.G. and Weiss, S.J. (1990) Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. Science 249, 178-181.
14. Rice, W.G., Schaeffer, C.A., McDougal, J.S. and Orloff, S.L. (1991) Nature of inhibitors of HIV in human secretory fluids. Abstract, Contemporary Developments in Salivary Research, Buffalo, NY.
15. Rice, W.G., Schaeffer, C.A., Graham, L., Bu, M., McDougal, J.S., Orloff, S.L., Villinger, F., Young, M., Oroszlan, S., Fesen, M., Pommier, Y., Mendeleyev, J. and Kun, E. (1993a) The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc. Natl. Acad. Sci. USA 90, 9721-9724.
16. Rice, W.G., Schaeffer, C.A., Harten B., Villinger, F., South, T.L., Summers, M.F., Henderson, L.E., Bess, J.W., Jr., Arthur, L.O., McDougal, J.S., Orloff, S.L., Mendeleyev, J. and Kun, E. (1993b) Inhibition of HIV infectivity by zinc-ejecting C-nitroso compounds. Nature 361, 473-475.
17. Shepherd, V.L., Campbell, E.J., Senior, R.M. and Stahl, P.D. (1982) Characterization of the mannose/fucose receptor on human mononuclear phagocytes. RES: J. Ret. Soc. 32, 423-431.
18. Weislow, O.S., Kiser, R., Fine, D.L., Bader, J., Shoemaker, R.H. and Boyd, M.R. (1989) New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81, 577-586.
19. Yeh, C.-K., Handelman, B., Fox, P.C. and Baum, B.J. (1992) Further studies of salivary inhibition of HIV-1 infectivity. J. Acquir. Immune. Defic. Syndr. 5, 898-903.